| Literature DB >> 30038442 |
Abstract
Hereditary transthyretin amyloidosis is an inherited disorder that results in the gradual progressive deposit of abnormal protein called amyloid in the body's organs and tissues. There are currently no approved drugs to treat transthyretin amyloidosis, and patients may require liver transplantation for survival. There are a few drugs in development to treat hereditary transthyretin amyloidosis either by stabilizing the abnormal protein or by decreasing production of transthyretin. Both methods are being developed to slow progression of the disease.Entities:
Keywords: drug information; formulary management / P & T; investigational drugs
Year: 2018 PMID: 30038442 PMCID: PMC6050879 DOI: 10.1177/0018578718779757
Source DB: PubMed Journal: Hosp Pharm ISSN: 0018-5787